A groundbreaking injectable HIV prevention drug will be available for just $40 a year in over 100 countries by 2027, thanks to agreements between Unitaid, the Gates Foundation, and Indian pharmaceutical companies.
A groundbreaking partnership aims to provide low-cost lenacapavir to millions at risk of HIV in low- and middle-income countries, potentially transforming HIV prevention efforts worldwide.
The EU has recommended lenacapavir, an injectable drug for HIV prevention, which could drastically reduce transmission rates. With nearly 100% effectiveness, it promises a new era in combating HIV.
The European Medicines Agency has recommended the approval of lenacapavir, a twice-yearly injectable drug that could revolutionize HIV prevention and significantly reduce transmission rates globally.
The WHO's endorsement of lenacapavir, a twice-yearly injectable drug, could transform HIV prevention for high-risk groups, especially amid funding concerns. This breakthrough may help millions and push us closer to an AIDS-free world.
The FDA has approved lenacapavir, a groundbreaking antiviral drug for HIV prevention developed by biochemist Wesley Sundquist. Learn how this drug could change the future of HIV treatment and prevention.
A groundbreaking HIV prevention shot, Yeztugo, has been approved by the FDA, offering hope for at-risk individuals with its twice-yearly injections. However, concerns about cost and accessibility remain.
The FDA has approved Gilead's Yeztugo, a twice-yearly injection that could revolutionize HIV prevention, boasting a 99.9% effectiveness. While hailed as a breakthrough, concerns over pricing remain, with activists urging for affordability.
